Suppr超能文献

度普利尤单抗治疗难治性格罗弗病:一项病例研究。

Treatment of Refractory Grover's Disease With Dupilumab: A Case Study.

作者信息

McCarter Maclaine, Cleaver David, Lane Jordan

机构信息

Dermatology, A.T. Still University - Kirksville College of Osteopathic Medicine, Kirksville, USA.

Dermatology, Cleaver Dermatology, Kirksville, USA.

出版信息

Cureus. 2025 Jul 24;17(7):e88695. doi: 10.7759/cureus.88695. eCollection 2025 Jul.

Abstract

Grover's disease (GD) is a pruritic skin condition characterized by erythematous, scaly papules on the trunk, often resolving spontaneously but sometimes becoming persistent and difficult to manage. In this case study, we discuss a 73-year-old male with treatment-resistant GD who experienced significant improvement with dupilumab injections. Within two weeks, the patient reported noticeable improvement in pruritus and rash, with complete resolution achieved after five months of continued treatment and no notable adverse effects. This case can highlight dupilumab as a promising option for refractory GD, as well as support the hypothesis of an immune-mediated pathogenesis of GD.

摘要

格罗弗病(GD)是一种瘙痒性皮肤病,其特征为躯干上出现红斑性、鳞屑性丘疹,通常可自行消退,但有时会持续存在且难以处理。在本病例研究中,我们讨论了一名73岁患有难治性GD的男性患者,其使用度普利尤单抗注射后病情有显著改善。在两周内,患者报告瘙痒和皮疹有明显改善,持续治疗五个月后完全消退,且无明显不良反应。该病例可突出度普利尤单抗作为难治性GD的一种有前景的选择,同时也支持GD免疫介导发病机制的假说。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验